XUANZHUBIO-B (02575) continued to gain momentum in the afternoon trading session, peaking at HK$59.85, representing a staggering increase of over 415% from its IPO price of HK$11.6. As of the latest update, the stock is up by 29.67%, priced at HK$59, with a trading volume of HK$183 million. The surge comes after XUANZHUBIO announced it presented Phase III interim analysis results from the BRIGHT-3 study, investigating the combination of palbociclib with letrozole or anastrozole in HR+/HER2- advanced breast cancer. This presentation took place on October 20 at the European Society for Medical Oncology (ESMO) 2025 annual meeting in Germany. The BRIGHT-3 study is a randomized, double-blind Phase III clinical trial conducted at 58 centers across China, aiming to evaluate the efficacy and safety of palbociclib in combination with aromatase inhibitors as first-line treatment for HR+/HER2- advanced breast cancer. Based on the interim data from BRIGHT-3, the National Medical Products Administration of China officially accepted the new drug application for the use of palbociclib in combination with aromatase inhibitors on May 14.